Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Semaglutide access and health inequity
Semaglutide works. Access does not follow need. Here is what fill-rate, pricing and policy data show about who actually gets treated, and who does not.
Semaglutide and wet AMD: signal vs proof
A 2026 study flagged semaglutide among five drugs with raised wet AMD reporting. Here is what that kind of signal can and cannot tell you.
Tirzepatide vs Semaglutide Side Effects
A new adverse-event reporting study compares tirzepatide and semaglutide, but raw report counts alone cannot show which drug is riskier.
What is food noise? Five theories
A 2026 Appetite review says food noise still has no settled definition. Here are the five theories behind it, and what the GLP-1 survey data shows.
What Obesity Drug Cost Models Show
A systematic review of economic evaluations finds anti-obesity medicine cost-effectiveness varies by setting, price, assumptions, and comparator.
BPC-157 for a running injury: evidence
A runner's forum question reflects real interest in BPC-157, but animal studies and anecdotes do not establish safe or effective injury treatment.
Why a peptide list is not a treatment plan
A community peptide list can show what is being discussed, but it cannot establish safety, evidence or suitability for an individual.
GLP-1 Use After Bariatric Surgery
A retrospective cohort found no statistically significant weight-loss difference after bariatric surgery when GLP-1 medicines were started within a year.
Are healthcare systems ready for GLP-1s?
GLP-1 readiness requires continuity, transparent access rules and realistic expectations, not only an effective prescription.
HISTORI Semaglutide Record: What We Know
A PubMed record describes a semaglutide trial in schizophrenia, prediabetes, and obesity, but currently supplies no abstract or outcome data.
MASH combination therapy: review insights
A 2026 review explains why MASH combination therapy is being explored, while leaving major questions unresolved.
MASH eligibility tests: study findings
A multicentre cohort found that proposed non-invasive MASH eligibility criteria classified many patients differently.